The Child Neurology Society (CNS) is pleased to welcome Taysha Gene Therapies, a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, as our newest Mission Partner.
Taysha’s commitment to developing gene therapies for severe neurological conditions, with particular focus on Rett syndrome, makes them a valuable partner in our ongoing efforts to support child neurologists with specialized education and clinical insights. Their focus on genetics and precision approaches to Rett syndrome management reflects the evolution of care that our members need to understand and implement.
“This partnership with Taysha Gene Therapies supports our educational mission as genetic therapies continue to reshape the landscape of rare disease treatment,” said Monique Terrell, Executive Director and CEO. “It is essential that child neurologists have access to current research and clinical developments in conditions like Rett syndrome. This partnership will provide valuable resources to our community.”
As a Mission Partner, Taysha will support educational initiatives in collaboration with the CNS to advance understanding of the underlying biology of Rett syndrome and the evolving approaches to treating rare genetic neurological diseases.
This partnership represents a meaningful investment in the mission of the CNS to support child neurologists through education and professional development and underscores our shared dedication to advancing care through innovation, education, and scientific excellence.